A Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy Study of TPI-287 in Alzheimer's Disease
Status:
Completed
Trial end date:
2019-09-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to determine the highest dose of TPI-287 that is safe and
tolerable when administered as an intravenous infusion to participants with mild to moderate
Alzheimer's disease (AD), to measure pharmacokinetic properties of the drug as well as to
gauge preliminary efficacy of TPI-287 on disease progression.